Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Australia / NCT04983823
Recruiting Not applicable

Persistent Cardiovascular Effects of COVID-19 Viral Infection Trial (PERCEIVE)

NCT04983823 · tracked via the Priya Life Science Australia tracker
Sponsor
Baker Heart and Diabetes Institute
Phase
Not applicable
Started
2021-11-18
Last updated
2025-10-03

Condition(s) studied

Heart Failure

Investigational drug(s) / intervention(s)

Heart Failure intervention (Cardiac COVID Disease Management Plan (CC-DMP)Usual care

Heart Failure intervention (Cardiac COVID Disease Management Plan (CC-DMP): A clinical review to ensure optimal risk factor control and cardioprotection along with exercise intervention.

Usual care: This will be provided by participants' usual healthcare professional(s).

Study summary

This is a prospective study in which a process of identifying and improving a reduction of functional capacity in COVID-19 survivors \>50 years old.

The overall goal of this study to identify the feasibility and value of risk-guided medical therapy and exercise intervention in COVID-19 survivors.

Eligibility

Sex
ALL
Min age
50 Years
Max age
85 Years
Healthy volunteers
Accepted
Inclusion Criteria: 1. History of COVID-19 infection 2. Live within a geographically accessible area for follow-up Exclusion Criteria: 1. Valvular stenosis or regurgitation of \>moderate severity 2. History of previous heart failure (baseline New York Heart Association (NYHA) classification \>2) 3. Inability to acquire interpretable images (identified from baseline echo) 4. Contraindications to beta blockers or angiotensin-converting enzyme inhibitors 5. Oncologic (or other) life expectancy \<12 months or any other medical condition (including pregnancy) that results in the belief (deemed by the Chief Investigators) that it is not appropriate for the patient to participate in this trial 6. Already taking both angiotensin converting enzyme inhibitors/ angiotensin receptor blockers and beta blockers, or intolerance (or allergy) to both. 7. Mobility impairment that would impact participants' ability to perform exercise 8. Unable to provide written informed consent to participate in this study

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Baker Heart and Diabetes Institute Melbourne Victoria Recruiting

More Baker Heart and Diabetes Institute trials in Australia

Exercise to Improve Neurovascular Function in Breast Cancer Survivors Starting soon
Echo Acquisition Despite Geographic Separation by Replication of Human Movements (EAGER) Starting soon
Risk-guided Disease managEment Plan to prevEnt CAD in Patients Treated With Previous Cancer Recruiting
Use of Artificial Intelligence-Guided Echocardiography to assIst cardiovascuLar Patient managEment Recruiting
Risk-guided Disease Management Plan to Prevent Heart Failure in Patients Treated With Previous Chemotherapy (REDEEM) Recruiting

Other trials for the same condition

Cardiac Resynchronization Therapy in Previously Untreatable and High Risk Upgrade Patients Active, not recruiting
REDUCE LAP-HF TRIAL II Active, not recruiting
ASCEND CSP IDE Study Active, not recruiting
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin Recruiting
A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04983823 on ClinicalTrials.gov ↗ ← All trials in Australia